Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluated the safety, tolerability and pharmacokinetics of single or multiple doses of EGT0001474.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Theracos
• Treatments: Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

• Male or female volunteers between the ages of 18 and 55 years inclusive.

• In good health.

• Female subjects must be surgically sterilized or postmenopausal.

• Body mass index (BMI) between 18 kg/m2 and 30 kg/m2 inclusive.

• Non-smoker.

• Negative drug and alcohol screens.

Exclusion Criteria:

• Abnormal ECG

• Sitting blood pressure above 140/90 mmHg on 2 evaluations at least 10 minutes apart at screening

• Treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.

• Previous treatment with EGT0001474.

• History of drug abuse.

• Febrile illness within 5 days prior to the first dose of study medication.